Boston, Massachusetts, (September 11, 2019)-Hosted by MyBioGate and CUBIO Innovation Center, sponsored by Simcere innovation, Jiangsu industrial technology institute, Merits & Tree law offices, Gracell Biotechnologies and Cello Health Bioconsulting, China [email protected] 2019 has taken place on September 10 at the Boston Convention and Exhibition Center in Boston.
China [email protected]
conference brought together 400+ attendees from around the world to learn about
China’s healthcare and pharmaceutical industry, hear about the latest NMPA
regulatory and reimbursement reforms and implications. It also provides a
valuable networking opportunity for attendees to meet with the decision-makers
in the industry through pre-conference partnering.
forum kicked off in the opening remark of Ms. Xinxin Li, Vice President of
Strategic Cooperation of MyBioGate. “With the rise of China healthcare market
and industry, there could be more therapeutics brought to the market, patient
community can access better healthcare with lower cost and entrepreneurs
developing new drugs can be supported and rewarded financially”, Xinxin
During the following keynotes and panels, the speakers shared their opinions on wide-ranging topics including cross-border partnership in a new era of globalization and innovation, Chinese biopharma’s diverse strategies to meet the domestic and global needs of innovation.
speech: Katherine Anderson – Head of U.S. Life Science & Healthcare
Relationship Banking, Silicon Valley Bank
investors have shown continued interest in supporting the global Life Science
and Healthcare innovation ecosystem with a staggering $17B invested during a
four-year period. When aggregated, European countries lead the way with $5.4B raised
from Chinese investors.” Ms. Katherine Andersen, Head of U.S. Life Science
& Healthcare Relationship Banking at Silicon Valley Bank addressed in her
keynote speech “China’s Role in Global Life Science and Healthcare”.
4 Winning recipes in a competitive landscape of licensing – What can we learn
from the experiences of recent deal makers?
The organizers of China [email protected] also invited the innovative projects to participate in the event’s featured session: Pitch & Match and MyBioGate Global Healthcare Innovation Competition generated fruitful results, based on attendees. Enterprises from China and the United States also carried out comprehensive exhibitions of their enterprise from products, brand concept and core competitiveness.
second annual China [email protected] conference was also held with an evening salon
sponsored by Simcere innovation. Harvey Lodish, Ph.D., Founding Member and
Professor, Whitehead Institute for Biomedical Research/MIT, Gordon J. Freeman,
Ph.D., Professor of Medicine, Harvard Medical School, and Z. Alex Xu, M.D.,
Ph.D., Chief Scientist, CFDA/CDE brought remarkable speech on cutting-edge
technological achievements in new therapies, new opportunities that China’s
recent drug regulatory reforms bring up.
Harvey Lodish – Founding Partner and Professor, Whitehead Institute of Biomedical Research/MIT
year, China Focus gathered 109 attendees in Boston for the very first meeting. “Over
the past year, MyBioGate organized China Focus in Boston, San Francisco, Vienna
and Philadelphia, gathered more than 1300 life science executives from all over
the world,” Ms. Xinxin Li addressed during the conference, “MyBioGate
will continue to make China Focus a platform for all stakeholders to explore
opportunities associated with the rising China healthcare market.”
more information, please visit: https://events.mybiogate.com/biotechweekboston/
next event China Focus @Europe Hamburg is slated for November 10 at Grand
Elysée Hamburg, Hamburg, Germany(https://events.mybiogate.com/europe/).
Focus is bringing together investors, pharma leaders and innovators from China
and around the world for an exclusive partnering event designed to inspire,
educate and foster cross-border investment and collaboration in leading
biopharma innovations. The forum features premier 1-to-1 networking
opportunities prior to and during the forum.
questions and inquiries: